natgillin/translations-raw huggingface dataset:
In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Od bolesnika s YMDD mutiranim HBV, 4/26 (15%) je imalo poboljšanje nekroinflamatornog rezultata, dok se u 8/26 (31%) bolesnika stanje pogoršalo u odnosu na ono prije liječenja.
In patients with the mutant, 4/26 (15 %) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Od bolesnika s YMDD tipom virusa, 4/26 (15%) je imalo poboljšanje nekroinflamatornog rezultata, dok se u 8/26 (31%) bolesnika stanje pogoršalo u odnosu na ono prije liječenja.
In patients with the mutant, 4/26 (15%) patients showed improvement in necroinflammatory score and 8/26 (31 %) patients worsened compared to pre- treatment.
Od bolesnika s YMDD mutiranim HBV, 4/26 (15%) je imalo poboljšanje nekroinflamatornog rezultata, dok se u 8/26 (31%) bolesnika stanje pogoršalo u odnosu na ono prije liječenja.
In patients with thrombocytopenia caused by the use of heparin, with or without thrombosis, enoxaparin sodium should be used with extreme caution.
U bolesnika s trombocitopenijom uzrokovanom primjenom heparina, sa ili bez tromboze, enoksaparin- natrij se treba primjenjivati s krajnjim oprezom.
In patients with thrombocytopenia caused by the use of heparin, with or without thrombosis, enoxaparin sodium should be used with extreme caution.
U bolesnika s trombocitopenijom uzrokovanom primjenom heparina, sa ili bez tromboze, enoksaparinnatrij se treba primjenjivati s krajnjim oprezom.
In patients with type 1 diabetes mellitus, treatment with Ryzodeg o.d. plus IAsp for the remaining meals demonstrated similar glycaemic control (HbA1c and fasting plasma glucose) with a lower rate of nocturnal hypoglycaemia compared to a basal/bolus regimen with IDet plus IAsp at all meals (Table 3).
U bolesnika sa šećernom bolešću tipa 1, liječenje lijekom Ryzodeg j.d. zajedno s IAsp uz ostale obroke pokazuje sličnu regulaciju glikemije (HbA1c i glukoza u plazmi natašte) uz nižu stopu noćnih hipoglikemija u usporedbi s bazal/bolus liječenjem s IDet zajedno s IAsp uz sve obroke (Tablica 3).
In patients with type 2 diabetes mellitus Ryzodeg can be administered alone, in combination with oral anti-diabetic medicinal products, and in combination with bolus insulin (see section 5.1).
U bolesnika sa šećernom bolešću tipa 2, Ryzodeg se može primjenjivati u monoterapiji, u kombinaciji s oralnim antidijabeticima te u kombinaciji s bolus inzulinom (vidjeti dio 5.1).
In patients with type 2 diabetes mellitus, Toujeo can also be given together with orally active antidiabetic medicinal products.
U bolesnika sa šećernom bolešću tipa 2, Toujeo se može primjenjivati zajedno s oralnim antidijabeticima.
In patients with type 2 diabetes mellitus, Tresiba can be administered alone or in any combination with oral anti-diabetic medicinal products, GLP-1 receptor agonists and bolus insulin (see section 5.1).
U bolesnika sa šećernom bolešću tipa 2, Tresiba se može primjenjivati u monoterapiji ili u bilo kojoj kombinaciji s oralnim antidijabeticima, agonistima GLP-1 receptora i s bolus inzulinom (vidjeti dio 5.1).
In patients with type 2 diabetes over a wide range of renal function the pharmacokinetic differences between insulin lispro and soluble human insulin were generally maintained and shown to be independent of renal function.
U bolesnika sa šećernom bolešću tipa 2 i različitim stupnjevima bubrežne funkcije farmakokinetičke razlike između inzulina lispro i topljivog humanog inzulina općenito su održane i ne ovise o bubrežnoj funkciji.
In patients with type 2 diabetes who received 2 doses of albiglutide 32 mg (Day 1 and 8), a statistically significant reduction (24%) in postprandial glucose AUC(0.5-4.5 h) was observed compared to placebo following a standardised breakfast meal on Day 9.
U bolesnika sa šećernom bolešću tipa 2 koji su primili 2 doze albiglutida od 32 mg (1. i 8. dana) primijećeno je statistički značajno smanjenje (24%) AUC(0,5-4,5h) glukoze postprandijalno u usporedbi s placebom nakon standardiziranog doručka 9. dana liječenja.
In patients with type 2 diabetes, NovoMix 50 can be given as monotherapy or in combination with metformin, when the blood glucose is inadequately controlled with metformin alone.
U bolesnika sa šećernom bolešću tipa 2 NovoMix 50 se može primjenjivati u monoterapiji ili u kombinaciji s metforminom kada vrijednosti glukoze u krvi nisu dovoljno regulirane samim metforminom.
In patients with type 2 diabetes, NovoMix 70 can be given as monotherapy or in combination with metformin, when the blood glucose is inadequately controlled with metformin alone.
U bolesnika sa šećernom bolešću tipa 2 NovoMix 70 se može primjenjivati u monoterapiji ili u kombinaciji s metforminom kada vrijednosti glukoze u krvi nisu dovoljno regulirane samim metforminom.
In patients with ulcerative colitis, mean steady-state serum trough concentrations were 11.2 mcg/ml (SD ± 7.24) and 38.3 mcg/ml (SD ± 24.43), respectively.
U bolesnika s ulceroznim kolitisom, srednja vrijednost najniže ravnotežne serumske koncentracije bila je 11,2 µg/ml (SD ± 7,24) odnosno 38,3 µg/ml (SD ± 24,43).
In patients with uncontrolled hypertension duloxetine should not be initiated (see section 4.3).
Ne smije se započeti liječenje duloksetinom u bolesnica s nekontroliranom hipertenzijom (vidjeti dio 4.3).
In patients with underlying cardiac disease, arrhythmias (such as atrial fibrillation and tachyarrhythmia), angina pectoris, acute coronary syndrome, myocardial infarction and heart failure have occurred when treated with Gazyvaro (see section 4.8).
U bolesnika s podležećom srčanom bolešću koji su liječeni lijekom Gazyvaro zabilježene su aritmije (poput fibrilacije atrija i tahiaritmije), angina pektoris, akutni koronarni sindrom, infarkt miokarda te zatajenje srca (vidjeti dio 4.8).
In patients with unrecognised DPD deficiency treated with capecitabine, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
U bolesnika s neprepoznatim deficitom DPD-a liječenih kapecitabinom može doći do po život opasne toksičnosti koja se manifestira kao akutno predoziranje (vidjeti dio 4.9).
In patients with unrecognised DPD deficiency treated with capecitabine, life-threatening toxicities manifesting as acute overdose may occur (see section 4.9).
U bolesnika s neprepoznatom deficijencijom DPD-a liječenih kapecitabinom može doći do po život opasne toksičnosti koja se manifestira kao akutno predoziranje (vidjeti dio 4.9).
In patients with uveitis, a loading dose of 80 mg adalimumab on Week 0 followed by 40 mg adalimumab every other week starting at Week 1, resulted in mean steady-state concentrations of approximately 8 to 10 g/mL.
U bolesnika s uveitisom, udarna doza adalimumaba od 80 mg u nultom tjednu i zatim 40 mg svaki drugi tjedan, počevši od 1. tjedna, dovela je do srednje vrijednosti koncentracija u stanju dinamičke ravnoteže od približno 8 – 10 µg/ml.
In patients with valvular heart disease, there was a higher incidence of ventricular arrhythmia events in vernakalant patients.
Bolesnici s bolešću srčanih zalistaka koji su primali vernakalant imali su veću incidenciju događaja ventrikularne aritmije.
In patients with varying degrees of renal impairment administered 20 mg IV Dynastat, parecoxib was rapidly cleared from plasma.
U bolesnika s različitim stupnjevima oštećenja funkcije bubrega kojima se intravenski dao Dynastat od 20 mg, parekoksib se brzo uklonio iz plazme.
In patients with very high urate levels (e.g. those undergoing cancer chemotherapy), treatment with uric acid-lowering medicines could lead to the build-up of xanthine in the urinary tract, with possible stones, even though this has not been observed in patients being treated with ADENURIC for Tumor Lysis Syndrome.
Kod bolesnika s vrlo visokom razinom urata (npr. onih koji su podvrgnuti kemoterapiji za rak), liječenje lijekovima koji snižavaju razinu mokraćne kiseline može dovesti do porasta ksantina u mokraćnom sustavu, s mogućim stvaranjem kamenaca, iako to nije opaženo kod bolesnika liječenih ADENURICOM kod sindroma tumorske lize.
In patients with wet AMD, DME and RVO, initially, three or more consecutive, monthly injections may be needed.
U bolesnika s vlažnim AMD-om, DME-om i RVO-om moguće je da će u početku biti potrebno tri ili više uzastopnih mjesečnih injekcija.
In patients with YMDD mutant HBV, addition of an alternative agent without cross- resistance to lamivudine should be considered.
U bolesnika s YMDD tipom virusa, treba razmotriti primjenu alternativnog lijeka bez ukrižene rezistencije s lamivudinom.
In patients without a primary mutation detected at baseline (N=60) (i.e.
U bolesnika u kojih na početku ispitivanja nije pronađena primarna mutacija (N=60) (tj.
In patients without antibody induction, if tacrolimus therapy is initiated intravenously, the recommended starting dose is 0.03 - 0.05 mg/kg/day (with Prograf 5 mg/ml concentrate for solution for infusion) as a continuous 24-hour infusion targeted to achieve tacrolimus whole blood concentrations of 15 - 25 nanogram/ml.
Ako se u bolesnika bez indukcije protutijela terapija takrolimusom započne intravenski, preporučena početna doza je 0,03 – 0,05 mg/kg na dan (s Prograf 5 mg/ml koncentratom za otopinu za infuziju) u obliku kontinuirane 24-satne infuzije s ciljem da se postignu koncentracije takrolimusa u punoj krvi od 15 do 25 nanogram/ml.
In patients without CHF the incidence of hypotension was not significantly different during the first 2 hours after dose in patients treated with vernakalant compared to patients receiving placebo (5.7% versus.
U bolesnika bez kongestivnog zatajenja srca incidencija hipotenzije u prva dva sata nakon primjene lijeka nije se značajno razlikovala u bolesnika liječenih vernakalantom u odnosu na one koji su primili placebo (5,7% naspram 5,2%).
In patients without decompensated cirrhosis requiring the addition of ribavirin to their treatment regimen (see Table 1), the daily dose of ribavirin is weight based (< 75 kg = 1,000 mg and
U pacijenata bez dekompenzirane ciroze čijem je terapijskom režimu potrebno dodati ribavirin (vidjeti tablicu 1) dnevna doza ribavirina temelji se na tjelesnoj težini (< 75 kg = 1000 mg i
In patients without the mutant, 20/27 (74 %) had improvements in necroinflammatory activity and 2/27 (7 %) had worsening.
Kod bolesnika bez tog tipa virusa, u 20/27 (74%) zabilježeno je poboljšanje nekroinflamatorne aktivnosti, a pogoršanje u 2/27 (7%).
In patients without YMDD mutant HBV, 14/22 (64 %) showed improvement in necroinflammatory score and 1/22 (5 %) patients worsened compared to pre-treatment.
U 14/22 (64%) bolesnika koji nisu imali YMDD tip virusa zabilježeno je poboljšanje nekroinflamatornog rezultata, dok se u 1/22 (5%) bolesnika stanje pogoršalo u odnosu na ono prije liječenja.
In patients  11 years of age not on dialysis, once the target haemoglobin has been achieved with once every two week dosing, Aranesp may be administered subcutaneously once monthly using an initial dose equal to twice the previous once every two week dose.
Kod bolesnika u dobi od 11 godina i starijih, koji nisu na dijalizi, kad je ciljni hemoglobin dostignut s jednom primjenom svaka 2 tjedna, Aranesp se može nastaviti primjenjivati supkutano jednom mjesečno, uz početnu dozu koja je dvostruko veća od prethodne, davane jednom svaka 2 tjedna.
In patients 75 years, fondaparinux should be used with care, as renal function decreases with age (see section 4.4).
U bolesnika starih 75 godina fondaparinuks treba koristiti uz oprez jer se bubrežna funkcija smanjuje s dobi (vidjeti dio 4.4).
In patients, as well as in healthy volunteers, the maximum concentration (Cmax) and area-under-the-concentration time curve (AUC) increase proportionally with increases in dose.
U bolesnika, kao i u zdravih dobrovoljaca, maksimalna koncentracija (Cmax) i površina ispod krivulje za koncentraciju u vremenu (AUC) povećavaju se proporcionalno s porastom doze.
In patients, baseline factor Xa and PT were influenced by the surgery resulting in a difference in the concentration-PT slope between the day post- surgery and steady state.
U bolesnika je na početne vrijednosti faktora Xa i PV-a utjecao kirurški zahvat, što je rezultiralo razlikom u nagibu pravca koncentracija-PV između vrijednosti dobivenih dan nakon kirurškog zahvata i vrijednosti u stanju dinamičke ravnoteže.
In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Grastofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, bilo djece ili odraslih, s teškom kongenitalnom, cikličkom ili idiopatskom neutropenijom s apsolutnim brojem neutrofila (ABN) od ≤ 0,5 x 109/l i teškim ili recidivirajućim infekcijama u anamnezi, dugotrajna primjena Grastofila indicirana je za povećanje broja neutrofila i smanjenje incidencije i trajanja događaja povezanih s infekcijom.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Biograstim se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Biograstima se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece ili odraslih s teškom kongenitalnom, cikličkom ili idiopatskom neutropenijom uz apsolutni broj neutrofila (ANC) ≤ 0,5 x 109/l i teškim ili ponavljajućim infekcijama u anamnezi, dugotrajna primjena filgrastima indicirana je za povećanje broja neutrofila i smanjenje incidencije i trajanja događaja povezanih s infekcijom.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Ratiograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Ratiograstima se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
In patients, children or adults, with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of  0.5 x 109 /l and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece ili odraslih s teškom kongenitalnom, cikličkom ili idiopatskom neutropenijom s apsolutnim brojem neutrofila (ABN)  0,5 × 109/l i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena filgrastima se koristi za povećanje broja neutrofila i za smanjenje učestalosti i trajanja poremećaja povezanih s infekcijom.
In patients, dasatinib has a large apparent volume of distribution (2,505 l) suggesting that the medicinal product is extensively distributed in the extravascular space.
Dasatinib u bolesnika ima velik volumen distribucije (2505 l), što znači da se lijek široko raspodjeljuje u ekstravaskularnom prostoru.
In patients, HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either the M41L or L210W reverse transcriptase mutation showed reduced susceptibility to tenofovir disoproxil fumarate.
Pacijenti u kojih je HIV-1 izražavao tri ili više mutacija povezanih s analogom timidina (TAMs; engl. thymidine-analoque associated mutations), koje su uključivale bilo M41L ili L210W mutaciju reverzne transkriptaze, pokazali su smanjenu osjetljivost na tenofovirdizoproksilfumarat.
In patients, mean Cmax (CV %) and AUCINF of artenimol (observed after the first dose of Eurartesim) were 752 (47%) ng/ml and 2,002 (45%) ng/ml*h, respectively.
U bolesnika je prosječni Cmax (CV%) artenimola iznosio 752 (47%) ng/ml, a prosječni AUCINF 2,002 (45%) ng/ml*h (opaženi nakon prve doze Eurartesima).
In patients, ZALTRAP is administered at the dose of 4 mg/kg intravenously every two weeks for which there is an excess of circulating free aflibercept compared to VEGF-bound aflibercept.
U bolesnika se ZALTRAP primjenjuje u intravenskoj dozi od 4 mg/kg svaka dva tjedna, pri čemu se u krvotoku postižu koncentracije slobodnog aflibercepta veće od koncentracija aflibercepta vezanog za VEGF.
In PBPC mobilisation in normal donors the most commonly reported undesirable effect was musculoskeletal pain.
Kod mobilizacije progenitorskih stanica periferne krvi u zdravih darivatelja, najčešće zabilježena nuspojava bila je mišićno-koštana bol.
In PBPC mobilisation in normal donors the most commonly reported undesirable effect was musculoskeletal pain.
U mobilizaciji progenitorskih stanica iz periferne krvi u zdravih davatelja najčešće zabilježena nuspojava bila je mišićno-koštana bol.
In PBPC mobilisation in normal donors, the most commonly reported undesirable effect was musculoskeletal pain.
U mobilizaciji krvotvornih matičnih stanica periferne krvi u zdravih davatelja najčešće zabilježeni neželjeni učinak bio je mišićno-koštana bol.
In PBPC mobilization in normal donors the most commonly reported undesirable effect was musculoskeletal pain.
Kod mobilizacije stanica preteča periferne krvi u zdravih darivatelja, najčešće zabilježena nuspojava bila je mišićno-koštana bol.
In Pegasys, the interferon alfa-2a has been ‘pegylated’ (attached to a chemical called polyethylene glycol).
Kod lijeka Pegasys interferon alfa2a je „pegiliran” (pričvršćen na kemijski spoj zvan polietilen-glikol).
In perennial allergic rhinitis, fluticasone furoate nasal spray 55 micrograms once daily exhibited a more consistent efficacy profile than fluticasone furoate nasal spray 110 micrograms once daily over 4 weeks’ treatment.
U cjelogodišnjem alergijskom rinitisu, sprej za nos koji sadržava flutikazonfuroat primijenjen u dozi od 55 mikrograma jednom na dan pokazao je konzistentniji profil djelotvornosti nego jednokratna dnevna doza od 110 mikrograma flutikazonfuroata tijekom 4-tjednog liječenja.
In perinatal and postnatal studies in rats, piperaquine was associated with delivery complications.
U perinatalnim i postnatalnim ispitivanjima u štakora piperakin je bio povezan s komplikacijama tijekom koćenja.
In Period A all patients received 10 mg/kg of abatacept on days 1, 15, 29, 57 and 85 and were assessed on day 113.
U Razdoblju A, svi su bolesnici primili abatacept u dozi od 10 mg/kg 1., 15., 29., 57. i 85. dana, a ocijenjeni su 113. dana.
In Period A, patients received placebo or Humira at an initial dose of 160 mg at Week 0 and 80 mg at Week 2 and 40 mg every week starting at Week 4 to Week 11.
Tijekom razdoblja A bolesnici su primali placebo ili lijek Humira u početnoj dozi od 160 mg u nultom tjednu i 80 mg u 2. tjednu, a zatim u dozi od 40 mg svaki tjedan, počevši od 4. tjedna pa sve do 11. tjedna.
In Period A, patients received placebo or Humira at an initial dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg every week starting at Week 4 to Week 11.
Tijekom razdoblja A bolesnici su primali placebo ili lijek Humira u početnoj dozi od 160 mg u nultom tjednu i 80 mg u 2. tjednu, a zatim u dozi od 40 mg svaki tjedan, počevši od 4. tjedna pa sve do 11. tjedna.
In period A, patients received placebo or Humira at an initial dose of 80 mg followed by 40 mg every other week starting one week after the initial dose.
U razdoblju A bolesnici su primali placebo ili lijek Humira u početnoj dozi od 80 mg, potom po 40 mg svaka dva tjedna, počevši tjedan dana nakon početne doze.
In permanent AF, the AF has been present for a long time (at least during 6 months) and a decision has been made not to change back your heart rhythm to atrial normal rhythm with a treatment called cardioversion, if you have or had a problem where your heart cannot pump the blood round your body as well as it should (condition called heart failure).
U slučaju permanentne fibrilacije atrija, fibrilacija je prisutna dulje vrijeme (najmanje 6 mjeseci) te je donesena odluka da se srčani ritam ne vraća u normalan atrijski ritam postupkom koji se zove kardioverzija, ako imate ili ste imali problem kod kojeg srce ne može pumpati krv tijelom onako kako bi trebalo (stanje koje se naziva zatajenjem srca).
In persons more than 2 years old with HFI, a spontaneous aversion for fructose-containing foods develops and may be combined with the onset of symptoms (vomiting, gastro-intestinal disorders, apathy, height and weight retardation).
U osoba s urođenom intolerancijom fruktoze starijih od 2 godine razvija se spontana averzija prema hrani koja sadrži fruktozu, a ona može biti povezana s nastupom simptoma (povraćanje, probavni poremećaji, apatija, zaostajanje u rastu i razvoju).
In pharmacodynamic studies in rabbits and guinea pigs, the thrombogenicity of Nonafact was shown to be minimal.
U farmakodinamičkim istraživanjima na kunićima i zamorcima pokazana je minimalna trombogenost lijeka Nonafact.
In pharmacokinetic studies that compared the absolute and relative bioavailability of Effentora and oral transmucosal fentanyl citrate (OTFC), the rate and extent of fentanyl absorption in Effentora demonstrated exposure that was between 30% to 50% greater than that for oral transmucosal fentanyl citrate.
U farmakokinetičkim studijama koje su uspoređivale apsolutnu i relativnu bioraspoloživost Effentore i oralnog fentanil citrata za primjenu kroz sluznicu usta (OTFC), brzina i stupanj apsorpcije fentanila kod Effentore pokazali su izloženost između 30 i 50% veću od one kod fentanil citrata za primjenu kroz sluznicu usta.
In pharmacokinetic studies with and without a charcoal blockage, BiResp Spiromax was evaluated by comparing it with an alternative authorised fixed-dose combination inhaled product containing the same active substances, budesonide and formoterol and has been shown to be equivalent in both systemic exposure (safety) and pulmonary deposition (efficacy).
U farmakokinetičkim ispitivanjima sa i bez blokade aktivnim ugljenom, BiResp Spiromax procijenjen je usporedbom s drugim odobrenim inhalacijskim lijekom koji sadrži kombinaciju fiksne doze istih djelatnih tvari, budezonida i formoterola te se pokazalo kako je jednak i u smislu sistemske izloženosti (sigurnost) i odlaganja u plućima (učinkovitost).